Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views?Zacks Investment Research • 07/14/25
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?Zacks Investment Research • 07/10/25
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 06/27/25
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular PipelineGlobeNewsWire • 06/26/25
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?Zacks Investment Research • 06/25/25
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street AnalystsThe Motley Fool • 06/21/25
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 06/18/25
CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/09/25
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/05/25
CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)Seeking Alpha • 06/03/25
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA TherapiesZacks Investment Research • 05/20/25
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?The Motley Fool • 05/20/25